Overview
The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.
Eligibility
Inclusion Criteria:
- request for cryopreserved ovarian tissue transplantation;
- premature ovarian failure or irregular mentrual cycles;
- negative test for HIV, HBV, HCV, Treponema pallidum;
- negative PAP test;
- oncological authorization;
- absence of neoplastic contamination in the cryopreserved ovarian tissue;
- Informed consent
Exclusion Criteria:
- neoplastic contamination in cryopreserved ovarian tissue;
- history of endometriosis;
- endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2);
- body mass index (BMI) >30 kg/m2;
- circulating platelet level < 150,000 / mml;
- bacterial infection;
- ongoing use of anticoagulants;
- bleeding diathesis.